• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼻内耐受在仙台病毒诱导的小鼠IgA肾病模型中的作用。

The role of nasal tolerance in a model of IgA nephropathy induced in mice by Sendai virus.

作者信息

Amore A, Coppo R, Nedrud J G, Sigmund N, Lamm M E, Emancipator S N

机构信息

Department of Nephrology and Dialysis, Regina Margherita Hospital, Turin, Italy.

出版信息

Clin Immunol. 2004 Oct;113(1):101-8. doi: 10.1016/j.clim.2004.06.002.

DOI:10.1016/j.clim.2004.06.002
PMID:15380535
Abstract

Mucosal antigenic exposure is implicated in pathogenesis of IgA nephropathy. Although IgG and/or IgM codeposits may promote disease, protracted mucosal antigenic exposure reduces IgG and IgM antibody, a process termed mucosal tolerance. We immunized mice intranasally with infectious or inactivated Sendai virus for 6 or 14 weeks. Anti-virus IgG remained high in mice given infectious virus for 14 weeks, but decreased after 6 weeks in mice given inactivated virus; IgA antibody remained high in both groups. Upon viral challenge, glomerular IgG and complement deposits and the frequency of hematuria, all equal after 6 weeks of immunization, were lower in mice immunized with inactivated virus for 14 weeks but remained high in mice given infectious virus; glomerular IgA increased over time in both immunized groups. Viremia in a non-tolerized immune host can promote glomerulonephritis with IgG and complement codeposits and glomerular dysfunction. These preliminary experiments may guide future, more mechanistic, investigation.

摘要

黏膜抗原暴露与IgA肾病的发病机制有关。虽然IgG和/或IgM共沉积可能会促进疾病发展,但长期的黏膜抗原暴露会降低IgG和IgM抗体水平,这一过程称为黏膜耐受。我们用感染性或灭活的仙台病毒对小鼠进行鼻内免疫,持续6周或14周。接受感染性病毒免疫14周的小鼠体内抗病毒IgG水平仍然很高,但接受灭活病毒免疫6周后的小鼠体内该抗体水平下降;两组小鼠体内的IgA抗体水平均保持较高。在病毒攻击后,免疫6周后肾小球IgG和补体沉积以及血尿频率均相同,但接受灭活病毒免疫14周的小鼠体内这些指标较低,而接受感染性病毒免疫的小鼠体内则仍然较高;两个免疫组的肾小球IgA均随时间增加。未耐受免疫宿主中的病毒血症可促进伴有IgG和补体共沉积以及肾小球功能障碍的肾小球肾炎。这些初步实验可能会为未来更具机制性的研究提供指导。

相似文献

1
The role of nasal tolerance in a model of IgA nephropathy induced in mice by Sendai virus.鼻内耐受在仙台病毒诱导的小鼠IgA肾病模型中的作用。
Clin Immunol. 2004 Oct;113(1):101-8. doi: 10.1016/j.clim.2004.06.002.
2
Experimental IgA-IgG nephropathy induced by a viral respiratory pathogen. Dependence on antigen form and immune status.由病毒性呼吸道病原体诱导的实验性IgA-IgG肾病。对抗原形式和免疫状态的依赖性。
Lab Invest. 1992 Sep;67(3):379-86.
3
The role of mesangial complement in the hematuria of experimental IgA nephropathy.系膜补体在实验性IgA肾病血尿中的作用。
Lab Invest. 1987 Sep;57(3):269-76.
4
Defective oral tolerance promotes nephritogenesis in experimental IgA nephropathy induced by oral immunization.口腔耐受缺陷会促进口服免疫诱导的实验性IgA肾病的肾发生。
J Immunol. 1990 Dec 1;145(11):3684-91.
5
Mucosal immunization of CD4+ T cell-deficient mice with an inactivated virus induces IgG and IgA responses in serum and mucosal secretions.用灭活病毒对CD4 + T细胞缺陷小鼠进行黏膜免疫可诱导血清和黏膜分泌物中产生IgG和IgA应答。
Virology. 2005 Jan 20;331(2):387-95. doi: 10.1016/j.virol.2004.10.014.
6
A case of IgA nephropathy associated with marked hematuria after upper respiratory tract infections.1例上呼吸道感染后伴明显血尿的IgA肾病。
Tokai J Exp Clin Med. 1982 Sep;7(5):583-7.
7
T cell cytokine polarity as a determinant of immunoglobulin A (IgA) glycosylation and the severity of experimental IgA nephropathy.T细胞细胞因子极性作为免疫球蛋白A(IgA)糖基化及实验性IgA肾病严重程度的一个决定因素。
Clin Exp Immunol. 2008 Sep;153(3):456-62. doi: 10.1111/j.1365-2249.2008.03703.x. Epub 2008 Jul 11.
8
Double immunofluorescence studies on IgA-associated immune-complexes in glomerular deposits in patients with IgA nephropathy.对IgA肾病患者肾小球沉积物中与IgA相关的免疫复合物的双重免疫荧光研究。
Tokai J Exp Clin Med. 1980 Apr;5(2):147-9.
9
Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.重组痘苗病毒对小鼠呼吸道仙台病毒感染的保护作用。
J Virol. 1997 Jan;71(1):832-8. doi: 10.1128/JVI.71.1.832-838.1997.
10
IgA nephropathy: lessons from an animal model, the ddY mouse.IgA肾病:来自动物模型ddY小鼠的经验教训。
J Nephrol. 2008 Jul-Aug;21(4):463-7.

引用本文的文献

1
The mucosal immune system and IgA nephropathy.黏膜免疫系统与 IgA 肾病。
Semin Immunopathol. 2021 Oct;43(5):657-668. doi: 10.1007/s00281-021-00871-y. Epub 2021 Oct 12.
2
The TLR4-MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy.TLR4-MyD88-NF-κB 通路参与 sIgA 介导的 IgA 肾病。
J Nephrol. 2020 Dec;33(6):1251-1261. doi: 10.1007/s40620-020-00722-3. Epub 2020 May 9.
3
Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.
呼吸道合胞病毒通过 C5a-C5aR1 轴协调 Th17 细胞反应加重 IgA 肾病小鼠的肾脏损伤。
Front Cell Infect Microbiol. 2019 May 7;9:151. doi: 10.3389/fcimb.2019.00151. eCollection 2019.
4
Primary IgA nephropathy: current challenges and future prospects.原发性IgA肾病:当前挑战与未来展望
Int J Nephrol Renovasc Dis. 2018 Apr 12;11:137-148. doi: 10.2147/IJNRD.S129227. eCollection 2018.
5
The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition.IgA 肾病的肠-肾轴:微生物组和饮食对遗传易感性的作用。
Pediatr Nephrol. 2018 Jan;33(1):53-61. doi: 10.1007/s00467-017-3652-1. Epub 2017 Apr 7.
6
Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.靶向C3a/C5a受体可抑制人系膜细胞增殖并减轻小鼠免疫球蛋白A肾病。
Clin Exp Immunol. 2017 Jul;189(1):60-70. doi: 10.1111/cei.12961. Epub 2017 Apr 10.
7
Immunoglobulin A nephropathy: a pathophysiology view.免疫球蛋白 A 肾病:病理生理学观点。
Inflamm Res. 2016 Oct;65(10):757-70. doi: 10.1007/s00011-016-0962-x. Epub 2016 Jun 28.
8
Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?扁桃体切除术能否改变IgA肾病中涉及的先天性和适应性免疫途径?
J Nephrol. 2015 Feb;28(1):51-8. doi: 10.1007/s40620-014-0086-8. Epub 2014 Apr 23.
9
Antiviral innate immunity disturbs podocyte cell function.抗病毒固有免疫会干扰足细胞的功能。
J Innate Immun. 2013;5(3):231-41. doi: 10.1159/000345255. Epub 2012 Dec 22.
10
Genetics and immunopathogenesis of IgA nephropathy.IgA 肾病的遗传学和免疫发病机制。
Clin Rev Allergy Immunol. 2011 Oct;41(2):198-213. doi: 10.1007/s12016-010-8232-0.